), one of the leading players in the global healthcare segment,
recently secured CE Mark approval for the commercial launch of its
Nellcor Respiration Rate System in the EU. Following the
announcement, shares of Covidien rose nearly 1.0%.
In addition to the Adult Respiratory Sensor, the system
incorporates the Nellcor Respiration Rate Version 2.0 software and
the Nellcor Bedside Respiratory Patient Monitoring System, both of
which recently received CE Mark approval.
The Nellcor devices from Covidien's oximetry and monitoring
products portfolio feature under the Medical Devices segment and
were approved by the U.S. Food and Drug Administration (FDA) a year
The Nellcor Respiratory Rate System is a single-sensor, pleth-based
respiration rate monitoring technology which allows clinicians to
monitor a patient's SpO2 (blood oxygen saturation), pulse rate and
respiration rate through a single integrated finger sensor.
Respiratory rates are critical to indicate early stages of
respiratory complications, which are often-missing factors in
patient monitoring reports. Through a continuous, non-invasive
patient monitoring platform, the Nellcor Respiration Rate System
provides critical information that enables the review of
respiratory trend data over the course of a patient's treatment.
The system reports respiration rates of ± 1 breath per minute when
compared to that derived from a capnography-based reference.
Compared to currently available methods, Covidien's Nellcor
respiratory system is accurate, easy to use and may enable earlier
medical intervention in case of a respiratory compromise.
The Nellcor Respiratory Function portfolio - a single integrated
sensor technology - is a significant development in the patient
monitoring industry. It provides a comprehensive picture of a
patient's overall respiratory status and has the potential to
improve patient outcomes and reduce treatment costs.
The Nellcor technology supports Covidien's goal of becoming the
front-runner in cutting-edge medical technology that enables
clinicians to provide better patient care.
Currently, Covidien retains a Zacks Rank #3 (Hold). Some
better-ranked medical product stocks worth considering are
Eagle Pharmaceuticals Inc.
). All these stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
COVIDIEN PLC (COV): Free Stock Analysis Report
To read this article on Zacks.com click here.